| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥14.77B | ¥12.51B | +18.1% |
| Cost of Sales | ¥8.09B | ¥5.99B | +35.2% |
| Gross Profit | ¥6.68B | ¥6.52B | +2.4% |
| SG&A Expenses | ¥6.63B | ¥6.44B | +2.9% |
| Operating Income | ¥49M | ¥80M | -38.8% |
| Non-operating Income | ¥1.74B | ¥1.94B | -10.5% |
| Non-operating Expenses | ¥161M | ¥195M | -17.5% |
| Ordinary Income | ¥1.63B | ¥1.83B | -11.0% |
| Profit Before Tax | ¥1.32B | ¥1.76B | -24.6% |
| Income Tax Expense | ¥286M | ¥443M | -35.5% |
| Net Income | ¥1.04B | ¥1.31B | -20.9% |
| Net Income Attributable to Owners | ¥1.06B | ¥1.33B | -20.3% |
| Total Comprehensive Income | ¥-968M | ¥3.54B | -127.3% |
| Depreciation & Amortization | ¥1.50B | ¥1.08B | +39.3% |
| Interest Expense | ¥126M | ¥94M | +34.5% |
| Basic EPS | ¥25.48 | ¥31.97 | -20.3% |
| Dividend Per Share | ¥20.00 | ¥20.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥31.38B | ¥32.94B | ¥-1.56B |
| Cash and Deposits | ¥11.56B | ¥12.03B | ¥-475M |
| Accounts Receivable | ¥6.04B | ¥6.64B | ¥-600M |
| Inventories | ¥12.73B | ¥12.62B | +¥117M |
| Non-current Assets | ¥59.59B | ¥59.48B | +¥118M |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥1.82B | ¥232M | +¥1.59B |
| Investing Cash Flow | ¥-4.15B | ¥-7.52B | +¥3.38B |
| Financing Cash Flow | ¥2.29B | ¥7.66B | ¥-5.37B |
| Free Cash Flow | ¥-2.33B | - | - |
| Item | Value |
|---|---|
| Book Value Per Share | ¥909.74 |
| Net Profit Margin | 7.2% |
| Gross Profit Margin | 45.2% |
| Current Ratio | 110.3% |
| Quick Ratio | 65.5% |
| Debt-to-Equity Ratio | 1.38x |
| Interest Coverage Ratio | 0.39x |
| EBITDA Margin | 10.5% |
| Effective Tax Rate | 21.6% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +18.1% |
| Operating Income YoY Change | -38.4% |
| Ordinary Income YoY Change | -11.0% |
| Net Income Attributable to Owners YoY Change | -20.3% |
| Total Comprehensive Income YoY Change | -46.6% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 41.63M shares |
| Treasury Stock | 564 shares |
| Average Shares Outstanding | 41.63M shares |
| Book Value Per Share | ¥918.19 |
| EBITDA | ¥1.55B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥20.00 |
| Year-End Dividend | ¥30.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| Medipolis | ¥390M | ¥14M |
| TranslationalResearch | ¥29M | ¥-2.08B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥33.27B |
| Operating Income Forecast | ¥3.55B |
| Ordinary Income Forecast | ¥5.93B |
| Net Income Attributable to Owners Forecast | ¥3.55B |
| Basic EPS Forecast | ¥85.27 |
| Dividend Per Share Forecast | ¥30.00 |
| Property, Plant & Equipment | ¥35.38B | ¥34.83B | +¥548M |
| Intangible Assets | ¥2.03B | ¥2.10B | ¥-70M |
| Goodwill | ¥1.78B | ¥1.88B | ¥-106M |
| Investment Securities | ¥19.54B | ¥19.76B | ¥-222M |
| Total Assets | ¥90.98B | ¥92.42B | ¥-1.44B |
| Current Liabilities | ¥28.46B | ¥29.26B | ¥-794M |
| Accounts Payable | ¥501M | ¥461M | +¥40M |
| Short-term Loans | ¥14.23B | ¥11.78B | +¥2.45B |
| Non-current Liabilities | ¥24.29B | ¥23.07B | +¥1.21B |
| Long-term Loans | ¥23.43B | ¥22.27B | +¥1.15B |
| Total Liabilities | ¥52.75B | ¥52.33B | +¥421M |
| Total Equity | ¥38.23B | ¥40.09B | ¥-1.86B |
| Capital Stock | ¥9.68B | ¥9.68B | ¥0 |
| Capital Surplus | ¥2.40B | ¥2.36B | +¥40M |
| Retained Earnings | ¥19.90B | ¥20.09B | ¥-188M |
| Treasury Stock | ¥-745,000 | ¥-745,000 | ¥0 |
| Owners' Equity | ¥37.87B | ¥40.02B | ¥-2.15B |
| Working Capital | ¥2.92B | - | - |